Frequently Asked Questions About Amedisys Inc (AMED) Stock
Amedisys Inc's (AMED) last reported annual revenue was USD 2.24 Billion.
Amedisys Inc's (AMED) annual revenue growth rate based on the revenue reported in the past 5 years is : 6.11%
Amedisys Inc's(AMED) is not profitable as of its last reported annual financials.
The net profit margin for Amedisys Inc's(AMED) from its laster reported year is -0.44%
The return on equity (ROE) for Amedisys Inc's(AMED) from its last reported annual financials is : 7.21%
The return on assets (ROA) for Amedisys Inc's(AMED) from its last reported annual financials is : 6.27%
The return on invested capital (ROIC) for Amedisys Inc's(AMED) from its last reported annual financials is : 7.17%
The Debt to Equity ratio for Amedisys Inc's(AMED) from its last reported annual financials is : 33.93%
The dividend yield for Amedisys Inc's(AMED) from its laster reported year is 0.00%
Amedisys Inc's(AMED) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMED !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
